{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:08:58Z","timestamp":1780553338122,"version":"3.54.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Recombinant adeno-associated virus (rAAV)-mediated delivery of neutralizing antibodies is a promising strategy for rapid and durable prophylaxis against SARS-CoV-2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated the long-term expression, pharmacokinetics, immunogenicity, biodistribution, and protective efficacy of an rAAV vector of serotype DJ encoding the single-domain antibody P2C5 fused to a human Fc fragment (P2C5-Fc) in mice and common marmosets (Callithrix jacchus). Animals received a single intramuscular administration of rAAV-P2C5-Fc at a dose of 1 \u00d7 10\u00b9\u00b3 vector genome copies per kg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Rapid antibody detection in serum was observed, reaching peak concentrations (Cmax) by approximately 120 days and remaining at protective levels for &amp;gt;480 days in mice and up to 1,120 days in marmosets. Neutralizing titers closely paralleled serum P2C5-Fc concentrations and provided complete protection against lethal intranasal challenge with SARS-CoV-2 variants B.1.1.1 (Wuhan D614G) and BA.5 (Omicron) even at late time points (216 and 460 days post-administration in mice). Biodistribution analysis showed predominant localization of rAAV at the injection site and regional lymph nodes with minimal off-target spread. Moderate anti-AAV capsid antibody responses were detected, while anti-drug antibodies against P2C5-Fc remained undetectable in both species.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings demonstrate that a single intramuscular injection of rAAV-P2C5-Fc results in rapid onset, sustained expression, and long-term protective efficacy against SARS-CoV-2 variants in two preclinical models, supporting the potential of this platform for durable vectored immunoprophylaxis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1829230","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:41:13Z","timestamp":1780551673000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates"],"prefix":"10.3389","volume":"17","author":[{"given":"Ekaterina I.","family":"Ryabova","sequence":"first","affiliation":[{"name":"N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem A.","family":"Derkaev","sequence":"additional","affiliation":[{"name":"N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias B.","family":"Esmagambetov","sequence":"additional","affiliation":[{"name":"N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail A.","family":"Dovgiy","sequence":"additional","affiliation":[{"name":"N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya V.","family":"Gordeychuk","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis)","place":["Moscow, Russia"]},{"name":"Institute for Translational Medicine and Biotechnology, Sechenov University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna V.","family":"Shuliakova","sequence":"additional","affiliation":[{"name":"N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa M.","family":"Hossain","sequence":"additional","affiliation":[{"name":"N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton A.","family":"Blinov","sequence":"additional","affiliation":[{"name":"N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna A.","family":"Iliukhina","sequence":"additional","affiliation":[{"name":"N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria M.","family":"Grousova","sequence":"additional","affiliation":[{"name":"N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya D.","family":"Zorkov","sequence":"additional","affiliation":[{"name":"N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria V.","family":"Avdoshina","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislav A.","family":"Gulyaev","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliy D.","family":"Apolokhov","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana V.","family":"Gulyaeva","sequence":"additional","affiliation":[{"name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina A.","family":"Favorskaya","sequence":"additional","affiliation":[{"name":"N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry V.","family":"Shcheblyakov","sequence":"additional","affiliation":[{"name":"N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L.","family":"Gintsburg","sequence":"additional","affiliation":[{"name":"N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis Y.","family":"Logunov","sequence":"additional","affiliation":[{"name":"N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"B1","unstructured":"WHO Coronavirus (COVID-19) Dashboard"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701501","article-title":"SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants","volume":"12","author":"Mart\u00ednez-Flores","year":"2021","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in The Lancet","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.888987","article-title":"The efficacy and effectiveness of the COVID-19 vaccines in reducing severe disease and mortality: a systematic review","volume":"10","author":"Mohammed","year":"2022","journal-title":"Front Public Health"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100747","article-title":"Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study","volume":"35","author":"Evans","year":"2023","journal-title":"Lancet Regional Health \u2013 Europe"},{"key":"B7","unstructured":"How soon after vaccination am I immune"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/v15010119","article-title":"Early treatment with monoclonal antibodies or convalescent plasma reduces mortality in non-vaccinated high-risk COVID-19 patients","volume":"15","author":"Th\u00fcmmler","year":"2022","journal-title":"Viruses"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.673699","article-title":"Vectored immunotherapeutics for infectious diseases: Recombinant AAV-based strategies for antibody delivery","volume":"12","author":"Zhan","year":"2021","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00449","article-title":"Long-term delivery of an anti-SIV monoclonal antibody with AAV","volume":"11","author":"Martinez-Navio","year":"2020","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.07.003","article-title":"Site-specific integration of functional transgenes into the human genome by adeno\/AAV hybrid vectors","volume":"10","author":"Recchia","year":"2004","journal-title":"Mol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00572-14","article-title":"Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus","volume":"21","author":"Adam","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nature10660","article-title":"Antibody-based protection against HIV infection by vectored immunoprophylaxis","volume":"481","author":"Balazs","year":"2012","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-022-00361-2","article-title":"Adeno-associated virus mediated expression of monoclonal antibody MR191 protects mice against Marburg virus and provides long-term expression in sheep","volume":"32","author":"Rghei","year":"2025","journal-title":"Gene Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01762-x","article-title":"Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial","volume":"28","author":"Casazza","year":"2022","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1218256","article-title":"rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of SARS-CoV-2 infection in mice","volume":"14","author":"Esmagambetov","year":"2023","journal-title":"Front Immunol"},{"key":"B18","volume-title":"Guide for the Care and Use of Laboratory Animals","year":"2011"},{"key":"B19","volume-title":"Vivarium Sourcebook","year":"2008"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.32607\/actanaturae.27372","article-title":"Experimental use of common marmosets (Callithrix jacchus) in preclinical trials of antiviral vaccines","volume":"16","author":"Gordeychuk","year":"2024","journal-title":"Acta Naturae"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.822159","article-title":"Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern","volume":"13","author":"Favorskaya","year":"2022","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.30895\/2221-996X-2021-21-4-266-278","article-title":"Comparison of different technologies for producing recombinant adeno-associated virus on a laboratory scale","volume":"21","author":"Ryabova","year":"2021","journal-title":"BIOpreparations: Prevention Diagnosis Treat"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.960937","article-title":"rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis","volume":"13","author":"Derkaev","year":"2022","journal-title":"Front Microbiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/s42003-023-05263-6","article-title":"Omicron sub-lineage BA.5 infection results in attenuated pathology in hACE2 transgenic mice","volume":"6","author":"Rizvi","year":"2023","journal-title":"Commun Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.840757","article-title":"Heterogeneous infectivity and pathogenesis of SARS-CoV-2 variants Beta, Delta and Omicron in transgenic K18-hACE2 and wildtype mice","volume":"4","author":"Tarr\u00e9s-Freixas","year":"2022","journal-title":"Front Microbiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.673699","article-title":"Vectored immunotherapeutics for infectious diseases: Can rAAVs be the game changers for fighting transmissible pathogens","volume":"12","author":"Zhan","year":"2021","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s42003-024-06529-3","article-title":"Influence of AAV vector tropism on long-term expression and Fc-\u03b3 receptor binding of an antibody targeting SARS-CoV-2","volume":"7","author":"Wagner","year":"2024","journal-title":"Commun Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009544","article-title":"Intranasal gene therapy to prevent infection by SARS-CoV-2 variants","volume":"17","author":"Sims","year":"2021","journal-title":"PloS Pathog"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.09.002","article-title":"Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants","volume":"31","author":"Sun","year":"2023","journal-title":"Mol Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15809","article-title":"Immunogenicity and humanization of single-domain antibodies","volume":"289","author":"Rossotti","year":"2022","journal-title":"FEBS J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-239509","article-title":"Induction of immune tolerance to FIX by intramuscular AAV gene transfer is independent of the activation status of dendritic cells","volume":"115","author":"Bharadwaj","year":"2010","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00649-08","article-title":"Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle","volume":"82","author":"Penaud-Budloo","year":"2008","journal-title":"J Virol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/mt.2011.287","article-title":"The AAV vector toolkit: poised at the clinical crossroads","volume":"20","author":"Asokan","year":"2012","journal-title":"Mol Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1134\/S0006297924070083","article-title":"Structural basis for evasion of new SARS-CoV-2 variants from the potent virus-neutralizing nanobody targeting the S-protein receptor-binding domain","volume":"89","author":"Sluchanko","year":"2024","journal-title":"Biochem (Mosc)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol Ther \u2013 Methods Clin Dev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991832","article-title":"A versatile toolkit for overcoming AAV immunity","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1829230\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:41:15Z","timestamp":1780551675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1829230\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2026.1829230"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1829230","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"article-number":"1829230"}}